ESLA Form 3: Director Jia Dengyao reports zero beneficial ownership

Rhea-AI Filing Summary

Estrella Immunopharma director Jia Dengyao filed an initial Form 3 reporting no securities beneficially owned in the company. The form lists Dengyao's relationship to the issuer as a director and provides a business address. Table entries indicate there are no non-derivative or derivative holdings to report, and the reporting person signed the filing certifying the accuracy of the statement.

Insights

Corporate Governance Expert

TL;DR: Director disclosed initial Form 3 with no beneficial ownership, a routine governance filing with limited market impact.

The filing documents that the reporting person serves as a director but does not beneficially own equity or derivative securities of the issuer. From a governance perspective this is a standard initial disclosure that establishes the director's current position and holdings. Because no securities are reported, there are no immediate insider trading constraints tied to existing holdings, though standard Section 16 obligations will apply to future transactions.

Securities Compliance Analyst

TL;DR: Routine Section 16 disclosure; absence of holdings means no material ownership change was reported.

The Form 3 is an initial statement required for certain insiders. It confirms the individual's status as a reporting person while explicitly noting zero direct or indirect beneficial ownership in the issuer. For compliance teams, this creates a clear baseline for monitoring any subsequent transactions that would require Forms 4 or 5.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jia Dengyao

(Last) (First) (Middle)

5858 HORTON STREET, SUITE 370

(Street)

EMERYVILLE, CA 9460

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/22/2025

3. Issuer Name and Ticker or Trading Symbol
Estrella Immunopharma, Inc. [ ESLA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Dengyao Jia	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Estrella Immunopharma (ESLA) report?

The Form 3 reports that director Jia Dengyao currently does not beneficially own any securities of Estrella Immunopharma.

What is Jia Dengyao's relationship to Estrella Immunopharma (ESLA)?

The filing lists Jia Dengyao as a director of Estrella Immunopharma.

Does the Form 3 show any derivative securities for ESLA owned by the reporting person?

No. The filing explicitly states there are no non-derivative or derivative securities beneficially owned by the reporting person.

Does this Form 3 create any immediate trading restrictions for the reporting person?

The Form 3 itself documents holdings but does not impose new restrictions; Section 16 reporting obligations apply for any future transactions that must be reported on Forms 4 or 5.

Where is the reporting person located according to the Form 3?

The address listed for the reporting person is 5858 Horton Street, Suite 370, Emeryville, CA 9460.